Alios BioPharma Presents Data on Its Anti-HCV Nucleotide

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alios BioPharma Presents Data on Its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C

SOUTH SAN FRANCISCO, CA--(Marketwired - Sep 15, 2014) - Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for viral diseases, presented the preclinical profile of one of its wholly-owned anti-hepatitis C virus (HCV) nucleotides (AL-335) at the American Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL) 2014 Special Conference on Hepatitis C on September 13 th in New York City. Based upon the favorable data presented in the poster session, along with additional preclinical studies, Alios intends to advance AL-335 into Phase 1 clinical trials in the fourth quarter of 2014.

The AASLD/EASL poster presented preclinical data of AL-335, a novel uridine nucleotide analog. The goal of the current study was to evaluate the antiviral activity and selectivity of AL-335. Results from the study showed that AL-335 demonstrates potent inhibition of HCV in the cell-based replicon assay across genotypes. Other positive data showed that the AL-335 NTP is a potent inhibitor of the HCV NS5B polymerase and functions as a chain terminator, and shows high selectivity for the viral polymerase and not human polymerases. In addition, both in cells and in vivo, AL-335 was shown to metabolize to provide very high levels of the corresponding AL-335 NTP, which has a long in vivo half-life.

Nucleotides have become an important component of interferon-free combination therapy for patients with chronic hepatitis C (CHC) and there are currently few representatives of this important class of compounds advancing clinically. The discovery and development of safe and efficacious nucleotide analogs remains an important need for the treatment of CHC. In addition to AL-335, Alios is advancing AL-516, a purine nucleotide analog and its second wholly-owned anti-HCV nucleotide, through preclinical development towards human clinical trials in 2015. 

"Although there has been tremendous progress in the treatment of chronic hepatitis C, new treatment alternatives are still needed," commented Dr. Lawrence M. Blatt, President and Chief Executive Officer of Alios. "The Alios purine and pyrimidine nucleotides AL-516 and AL-335 offer the potential for combination therapy that could be effective against all HCV genotypes, greatly simplifying therapy."

About Alios' Anti-HCV Nucleotides (AL-335 and AL-516)

AL-335 and AL-516 are nucleotide analog polymerase inhibitors, a class of compounds that has emerged as a key component of interferon-free combination regimens used in the treatment of chronic hepatitis C. As substrates of the HCV polymerase NS5B, this class of compounds has demonstrated high in vitro potency and good clinical efficacy, with a high barrier to the development of resistance. AL-335 is a uridine based nucleotide analog and AL-516 is a guanosine based nucleotide analog. Both are novel compounds that have demonstrated desirable profiles in preclinical studies and have the potential to be used in combination to create an all oral, fixed-dose, pan-genotypic, once daily, short duration solution for patients with chronic hepatitis C. AL-335 is expected to enter clinical development in Q4 2014. Both AL-335 and AL-516 are wholly owned by Alios BioPharma.

About Alios BioPharma Alios BioPharma is a clinical stage biopharmaceutical company in South San Francisco, CA that is developing novel antiviral therapies for the treatment of viral diseases. The Alios virology discovery and development platform consists of a proprietary chemical library of nucleoside analogs as well as novel, proprietary virology-based screening systems. Alios is developing a portfolio of potential therapeutics for viral infections including RSV, influenza, rhinovirus, coronavirus and HCV. For more information please visit www.aliosbiopharma.com .

NOTE: A poster on the preclinical properties of AL-516 will be presented at the AASLD 'The Liver Meeting' being held in Boston from November 7 through 11.

Alios BioPharma Contact: Bharath Kumandan (Investors & Media) 650-635-5561 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 352

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 377

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

YouTube Shuts Down Tenet Media Channel Amid Legal Issues

Updated Category News Views 305

YouTube's Action Against Tenet Media Explained YouTube, which is part of Alphabet (NASDAQ: GOOGL), has made a significant move by shutting down the Tenet Media channel, along with four other channels managed by Lauren Chen. This decision comes in response to serious legal actions taken by the U.S. Department of Justice against certain individuals involved in money...

Continue Reading
Ardelyx Faces Class Action Lawsuit Amidst Investment Losses

Updated Category News Views 112

Important Update for Ardelyx Investors Regarding Class Action Pomerantz LLP has recently informed shareholders about a class action lawsuit involving Ardelyx, Inc. This lawsuit targets both the company and its key officers, alleging violations of federal securities laws. Investors who held Ardelyx securities during a specified timeframe should pay close attention to this...

Continue Reading
Derek Bryson Park: Innovator Transforming Finance Worldwide

Updated Category News Views 205

Celebrating Derek Bryson Park's Impact on Finance Derek Bryson Park has recently been highlighted by The Enterprise World Magazine as a key figure in the financial industry, a well-deserved recognition for his extensive and impactful career. With three decades of experience, Park continues to innovate in finance, public service, and global diplomacy. Pioneering Leadership...

Continue Reading
Understanding Currency Impacts in Global Trade Dynamics

Updated Category News Views 291

Understanding Currency Impacts in Global Trade Dynamics Scott Bessent, a noted figure in finance, is igniting conversations regarding tariffs and trade in recent discussions. All eyes on Wall Street are focused on how these changes influence market dynamics. Initially, any reduction in the U.S. trade deficit with other nations may seem like a significant win for the...

Continue Reading
Pennant Group Expands Its Operations with Recent Acquisition

Updated Category News Views 283

Pennant Group's Strategic Acquisition Announcement The Pennant Group, Inc. (NASDAQ: PNTG), a prominent holding company in the healthcare industry, recently achieved a significant milestone by acquiring specific operational assets from UnitedHealth Group Incorporated. This notable transaction was made possible due to UnitedHealth’s acquisition of Amedisys Inc., enabling...

Continue Reading